According to Wu Zhen, deputy director of CFDA, the main business income of China's 5,000 pharmaceutical companies has reached 2.5 trillion yuan (370 billion US dollars).
Up to 50 of the companies are certified in Europe or the United States, and their export volume surpassed 13.5 billion US dollars, Wu said.
Wu said the CFDA's efforts to speed up the process of new drug approval and clear the backlog of applications have paid off.
